Carl Sailer Biography and Net Worth



Mr. Sailer’s career extends almost 30 years as a commercial leader in the biopharmaceutical industry. He is currently Senior Vice President, Global Client Solutions for Syneos Health, a fully integrated biopharmaceutical solutions company that is expertised in taking new therapies to market, from clinical stage through commercial stage.  Mr. Sailer leads global customer-centric commercial account teams for two of the company's leading large pharma clients. Prior to Syneos Health, Mr. Sailer served as the Vice President of Sales and Marketing for Emisphere Technologies (ultimately acquired by Novo Nordisk), Vice President of Commercial Operations at New American Therapeutics (ultimately acquired by Renaissance Pharma) and Akrimax Pharmaceuticals, in each case, where he built and led the commercial organizations for each start-up company.

Previously, Mr. Sailer was a member of the Executive Committee at PDI, a leading contract commercial organization, where he held several leadership positions in product commercialization and business development. Mr. Sailer started his career by holding various sales, marketing and sales management roles in the pharmaceutical and consumer products divisions of Bristol-Myers Squibb and Bayer Healthcare.

Mr. Sailer earned an MBA from Hofstra University, and a BS in marketing with a minor in journalism from Seton Hall University, where he has been an adjunct graduate school professor and currently serves on the Advisory Board of the Market Research Center at the Stillman School of Business.

What is Carl Sailer's net worth?

The estimated net worth of Carl Sailer is at least $216,258.95 as of July 27th, 2022. Mr. Sailer owns 92,815 shares of Acurx Pharmaceuticals stock worth more than $216,259 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Sailer may own. Learn More about Carl Sailer's net worth.

How do I contact Carl Sailer?

The corporate mailing address for Mr. Sailer and other Acurx Pharmaceuticals executives is , , . Acurx Pharmaceuticals can also be reached via phone at 917-533-1469 and via email at [email protected]. Learn More on Carl Sailer's contact information.

Has Carl Sailer been buying or selling shares of Acurx Pharmaceuticals?

Carl Sailer has not been actively trading shares of Acurx Pharmaceuticals in the last ninety days. Most recently, on Wednesday, July 27th, Carl Sailer bought 19,737 shares of Acurx Pharmaceuticals stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $75,000.60. Following the completion of the transaction, the director now directly owns 92,815 shares of the company's stock, valued at $352,697. Learn More on Carl Sailer's trading history.

Who are Acurx Pharmaceuticals' active insiders?

Acurx Pharmaceuticals' insider roster includes Robert DeLuccia (Director), David Luci (CEO), and Carl Sailer (Director). Learn More on Acurx Pharmaceuticals' active insiders.

Carl Sailer Insider Trading History at Acurx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2022Buy19,737$3.80$75,000.6092,815View SEC Filing Icon  
11/23/2021Buy5,161$4.84$24,979.24View SEC Filing Icon  
See Full Table

Carl Sailer Buying and Selling Activity at Acurx Pharmaceuticals

This chart shows Carl Sailer's buying and selling at Acurx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acurx Pharmaceuticals Company Overview

Acurx Pharmaceuticals logo
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
Read More

Today's Range

Now: $2.33
Low: $2.05
High: $2.44

50 Day Range

MA: $3.02
Low: $1.94
High: $4.02

2 Week Range

Now: $2.33
Low: $1.17
High: $8.82

Volume

86,698 shs

Average Volume

180,824 shs

Market Capitalization

$36.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A